EORTC Melanoma Group Protocol 18071
Adjuvant immunotherapy with anti-CTLA-4 monclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase III trial of the EORTC Melanoma Group.
Contact person: Dr Pauline Hanrahan, Newcastle Melanoma Unit phone: 02 4985 0179
Inclusion Criteria:
Patients who have positive sentinel nodes that have been completely resected. Stage III melanoma.
